Aurealis Therapeutics announces 7.8MCHF financing to advance the chronic wound lead candidate AUP-16 to diabetic foot ulcer patients under new brand Aurealis Therapeutics AG

Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds and cancer announced 7.8MCHF funding provided by Swiss and foreign private investors, Finnvera plc, and Business Finland โ€“ the Finnish Innovation Funding Agency. The Company also confirmed the de-merger and a plan to develop and commercialize the AUP-16 under a […]